The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury

Li,Qi; Wu,Xiayang; Liu,Yanli; Zhang,Mingyu; Bai,Xue; Chen,Chang

doi:10.3892/mmr.2017.7667

The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury

Authors:
- Qi Li
- Xiayang Wu
- Yanli Liu
- Mingyu Zhang
- Xue Bai
- Chang Chen
View Affiliations

Affiliations: Biotherapy Center, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Pharmacology (State‑Province Key Laboratories of Biomedicine‑Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/mmr.2017.7667
Pages: 8003-8010
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study evaluated the effect of anagliptin on intimal hyperplasia following carotid artery injury in Sprague‑Dawley rats. Sprague‑Dawley rats weighing 280‑300 g were injured using a 2F Fogarty balloon embolectomy catheter. The rats were divided into injury‑(saline) and anagliptin‑(10 mg/kg/day) treated groups. vascular injuries were induced in the left carotid artery, followed by evaluation of neointima formation at 28 days. The right and left carotid arteries were harvested and evaluated with histological evaluation, and the plasma activity of glucagon‑like peptide 1 receptor (GLP‑1), stromal cell‑derived factor (SDF)‑1α, interleukin (IL)‑6, IL‑1β and tumor necrosis factor (TNF)‑α were detected by ELISA analysis. Treatment with anagliptin decreased balloon injury‑induced neointima formation, compared with the injury group (P<0.01). Body weight and food consumption did not alter following treatment with anagliptin. Anagliptin caused an increase in the serum active GLP‑1 concentration, compared with the injury group. In addition, serum SDF‑1α was significantly decreased by treatment with anagliptin (P<0.001). Anagliptin altered the serum activity of IL‑6, IL‑1β and TNF‑α (P<0.01). The results of the present study demonstrated that anagliptin appeared to attenuate neointimal formation by inhibiting inflammatory cytokines and chemokines following balloon injury, and that treatment with a dipeptidyl peptidase 4 inhibitor may be useful for future preclinical studies and potentially for the inhibition of thrombosis formation following percutaneous coronary intervention.

View Figures

View References

1	Molina JA and Heng BH: Global trends in cardiology and cardiothoracic surgery-an opportunity or a threat? Ann Acad Med Singapore. 38:541–545. 2009.PubMed/NCBI
2	Uchida Y, Uchida Y, Matsuyama A, Koga A, Kanai M and Sakurai T: Formation of web- and membrane-like structures on the edges of bare-metal coronary stents. Circ J. 74:1830–1836. 2010. View Article : Google Scholar : PubMed/NCBI
3	Pauletto P, Sartore S and Pessina AC: Smooth-muscle-cell proliferation and differentiation in neointima formation and vascular restenosis. Clin Sci (Lond). 87:467–479. 1994. View Article : Google Scholar : PubMed/NCBI
4	Delafontaine P: Growth factors and vascular smooth muscle cell growth responses. Eur Heart J. 19 Suppl G:G18–G22. 1998.PubMed/NCBI
5	Ross R: Cell biology of atherosclerosis. Annu Rev Physiol. 57:791–804. 1995. View Article : Google Scholar : PubMed/NCBI
6	Chervu A and Moore WS: An overview of intimal hyperplasia. Surg Gynecol Obstet. 171:433–447. 1990.PubMed/NCBI
7	Allaire E and Clowes AW: Endothelial cell injury in cardiovascular surgery: The intimal hyperplastic response. Ann Thorac Surg. 63:582–591. 1997.PubMed/NCBI
8	Hong WJ, Petell JK, Swank D, Sanford J, Hixson DC and Doyle D: Expression of dipeptidyl peptidase IV in rat tissues is mainly regulated at the mRNA levels. Exp Cell Res. 182:256–266. 1989. View Article : Google Scholar : PubMed/NCBI
9	Matheeussen V, Baerts L, de Meyer G, de Keulenaer G, van der Veken P, Augustyns K, Dubois V, Scharpé S and De Meestre I: Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem. 392:189–198. 2011. View Article : Google Scholar : PubMed/NCBI
10	Shinjo T, Nakatsu Y, Iwashita M, Sano T, Sakoda H, Ishihara H, Kushiyama A, Fujishiro M, Nishimura F and Asano T: High-fat diet feeding significantly attenuates anagliptin-induced regeneration of islets of Langerhans in streptozotocin-induced diabetic mice. Diabetol Metab Syndr. 7:502015. View Article : Google Scholar : PubMed/NCBI
11	Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S, Sukmawati D, Nomiyama T, Kanazawa A, Kawamori R, et al: Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 154:1260–1270. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hirano T, Yamashita S, Takahashi M, Hashimoto H, Mori Y and Goto M: Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits. Metabolism. 65:893–903. 2016. View Article : Google Scholar : PubMed/NCBI
13	Indolfi C, Pavia M and Angelillo IF: Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol. 95:1146–1152. 2005. View Article : Google Scholar : PubMed/NCBI
14	Cassess S, Hoppmann P, Kufner S, Byrne RA, Wiebe J, Colleran R, Giacoppo D, Harada Y, Laugwitz KL, Schunkert H, et al: Intraindividual comparison of everolimus eluting bioresorbable vascular scaffolds versus drug eluting metallic stent. Circ Cardiovasc Interv. 9:pii: e0036982016. View Article : Google Scholar
15	Allagnat F, Dubuis C, Lambelet M, Le Gal L, Alonso F, Corpataux JM, Déglise S and Haefliger JA: Connexin37 reduces smooth muscle cell proliferation and intimal hyperplasia in a mouse model of carotid artery ligation. Cardiovasc Res. 113:805–816. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, He X, Chen X, Ma H, Liu D, Luo J, Du Z, Jin Y, Xiong Y, He J, et al: Enhanced external counterpulsation inhibits intimal hyperplasia by modifing shear stress responsive gene expression in hypercholesterolemic pigs. Circulation. 116:526–534. 2007. View Article : Google Scholar : PubMed/NCBI
17	Davies MG and Hagen PO: The vascular endothelium. A new horizon. Ann Surg. 218:593–609. 1993. View Article : Google Scholar : PubMed/NCBI
18	Kibos A, Campeanu A and Tintoiu I: Pathophysiology of coronary artery in-stent restenosis. Acute Card Care. 9:111–119. 2007. View Article : Google Scholar : PubMed/NCBI
19	Yoneda S, Abe S, Kanaya T, Oda K, Nishino S, Kageyama M, Taguchi I, Masawa N and Inoue T: Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation. Coron Artery Dis. 24:368–373. 2013. View Article : Google Scholar : PubMed/NCBI
20	McDonald RA, Halliday CA, Miller AM, Diver LA, Dakin RS, Montgomery J, McBride MW, Kennedy S, McClure JD, Robertson KE, et al: Reducing in-stent restenosis: Therapeutic manipulation of miRNA in vascular remodeling and inflammation. J Am Coll Cardiol. 65:2314–2327. 2015. View Article : Google Scholar : PubMed/NCBI
21	Paneghetti L and Ng YS: A novel endothelial-derived anti-inflammatory activity significantly inhibits spontaneous choroidal neovascularisation in a mouse model. Vasc Cell. 8:22016. View Article : Google Scholar : PubMed/NCBI
22	Jiang W, Zheng B, Zhang XH, Yue LY, Liu C, Ma D, Yang Z and Wen JK: Tongxinluo inhibits neointimal formation by regulationg the expression and post-translational modification of KLF5 in macrophages. Am J Transl Res. 8:4778–4790. 2016.PubMed/NCBI
23	Zhang YQ, Tian F, Zhou Y, Chen YD, Li B, Ma Q and Zhang Y: Nicorandil attenuates carotid intimal hyperplasia after balloon catheter injury in diabetic rats. Cardiovasc Diabetol. 15:622016. View Article : Google Scholar : PubMed/NCBI
24	Grus T, Lambert L, Matěcha J, Grusová G, Špaček M and Mlček M: The ratio of diameters between the target artery and the bypass modifies hemodynamic parameters related to intimal hyperplasia in the distal end to side anastomosis. Physiol Res. 65:901–908. 2016.PubMed/NCBI
25	Honda Y, Kitano T, Fukuya F, Sato Y, Iwama S, Morie T and Notake M: A novel alphavbeta3 integrin antagonist suppresses neointima formation for more than 4 weeks after balloon injury in rats. Arterioscler Thromb Vasc Biol. 25:1376–1382. 2005. View Article : Google Scholar : PubMed/NCBI
26	Touchard AG and Schwartz RS: Preclinical restenosis models: Challenges and successes. Toxicol Pathol. 34:11–18. 2006. View Article : Google Scholar : PubMed/NCBI
27	Shinjo T, Nakatus Y, Iwashita M, Sano T, Sakoda H, Ishihara H, Kushiyama A, Fujishiro M, Nishimura F and Asano T: High-fat diet feeding significantly attenuates anagliptin-induced regeneration of islets of Langerhans in streptozotocin-induced diabetic mice. Diabetol Metab Syndr. 7:502015. View Article : Google Scholar : PubMed/NCBI
28	Lim S, Choi SH, Shin H, Cho BJ, Park HS, Ahn BY, Kang SM, Yoon JW, Jang HC, Kim YB and Park KS: Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One. 7:e350072012. View Article : Google Scholar : PubMed/NCBI
29	Eom YS, Gwon AR, Kwak KM, Kim JY, Yu SH, Lee S, Kim YS, Park IB, Kim KW, Lee K and Kim BJ: Protective effects of vildagliptin against pioglitazone induced bone loss in type 2 diabetic rat. PLoS One. 11:e01685692016. View Article : Google Scholar : PubMed/NCBI
30	Mentlein R: Dipeptidyl peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 85:9–24. 1999. View Article : Google Scholar : PubMed/NCBI
31	Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, et al: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 393:591–594. 1998. View Article : Google Scholar : PubMed/NCBI
32	Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P and Luster AD: The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res. 86:131–138. 2000. View Article : Google Scholar : PubMed/NCBI
33	Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T and Honji T: Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 28:495–500. 1995. View Article : Google Scholar : PubMed/NCBI
34	Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, et al: Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA. 95:pp. 6331–6336. 1998; View Article : Google Scholar : PubMed/NCBI
35	Schober A, Knarren S, Lietz M, Lin EA and Weber C: Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation. 108:2491–2497. 2003. View Article : Google Scholar : PubMed/NCBI
36	Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S, Sukmawati D, Nomiyama T, Kanazawa A, Kawamori R, et al: Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 153:1260–1270. 2013. View Article : Google Scholar
37	Lambeir AM, Durinx C, Scharpe S and De Meester I: Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 40:209–294. 2003. View Article : Google Scholar : PubMed/NCBI
38	Gorrell MD, Gysbers V and McCaughan GW: CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol. 54:249–264. 2001. View Article : Google Scholar : PubMed/NCBI
39	Zernecke A, Schober A, Bot I, Von Hundelshausen P, Liehn EA, Möpps B, Mericskay M, Gierschik P, Biessen EA and Weber C: SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res. 96:784–791. 2005. View Article : Google Scholar : PubMed/NCBI
40	Akita K, Isoda K, Shimada K and Daida H: Dipeptidyl-Peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice. J Am Heart Assoc. 4:e0014692015. View Article : Google Scholar : PubMed/NCBI
41	Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Müller S, et al: Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 60:1917–1925. 2011. View Article : Google Scholar : PubMed/NCBI
42	Murohara T: Dipeptidyl peptidase-4 inhibitor: Another player for cardiovascular protection. J Am Coll Cardiol. 59:277–279. 2012. View Article : Google Scholar : PubMed/NCBI